ClinicalTrials.gg
CompletedNCT04452669VPCOVIDUpdated Jul 31, 2025Results posted

VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation

A Phase 2 interventional study of VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) in COVID-19, sponsored by Aerogen Pharma Limited. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Aerogen Pharma Limited · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
1,127th of 1,322
11 · median 92
Started
2020
with 817 others
Phase 2
350 of 1,860
15 open now
Registered
490th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 1,127th largest by enrollment of the 1,322 interventional ones that give a count, is one of 818 that started in 2020, is one of 350 in phase 2, and was the 490th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether inhaled epoprostenol given via a breath actuated delivery system will help improve oxygen levels and treatment outcomes in patients with COVID-19 who are on mechanical ventilation.

Read the detailed description

This study will evaluate the potential therapeutic benefit of VentaProst in treating patients with COVID-19 at risk for respiratory and/ or cardiac/circulatory failure. This is a double-blind, placebo controlled study of VentaProst in 10 confirmed COVID-19 patients compared to 10- COVID-19 placebo patients to assess the efficacy and safety of VentaProst given over 10 days at varying doses.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • ARDS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed COVID-19 positive by RT-PCR test
  • Patients who require invasive mechanical ventilation.
  • Consent or professional consent obtained

Exclusion criteria

Exclusion Criteria:

  • Patients on ECMO support.
  • Patients receiving another inhalation research medication or inhaled nitric oxide.
  • Not expected to survive for 48 hours.
  • Allergy to Epoprostenol and its diluent
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Study Treatment

    Up to 10 days of inhaled epoprostenol delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.

    Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)

  • Placebo comparator
    Placebo Control

    Up to 10 days of inhaled 0.9% sodium chloride solution delivered by a breath actuated dedicated delivery system for patients with COVID-19 who are mechanically ventilated.

    Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)

Interventions

  • DrugEpoprostenolStudies of EpoprostenolEpoprostenol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.

    Also known as: inhaled Flolan

06

What researchers measure

Primary outcomes

  1. Change in Respiratory Failure

    Number of participants that were extubated

    Time frame: 10 days post-randomization

  2. Change in Cardiac/Circulatory Failure

    Number of participants that required ECMO or left ventricular assist device (LVAD)

    Time frame: 10 days post-randomization

07

Results

Posted Jul 31, 2025

Participant flow

Participant flow — Overall Study
MilestoneStudy TreatmentPlacebo Control
Started65
Completed51
Not completed14
Withdrew: Death14

Outcome measures

PrimaryChange in Respiratory Failure

Number of participants that were extubated

Time frame:
10 days post-randomization
Reported as:
Count of participants · Participants
Change in Respiratory Failure
ParticipantsStudy TreatmentPlacebo Control
Change in Respiratory Failure32
PrimaryChange in Cardiac/Circulatory Failure

Number of participants that required ECMO or left ventricular assist device (LVAD)

Time frame:
10 days post-randomization
Reported as:
Count of participants · Participants
Change in Cardiac/Circulatory Failure
ParticipantsStudy TreatmentPlacebo Control
Change in Cardiac/Circulatory Failure00

Adverse events

Collected over Adverse event data were collected from randomization through 28 days post-randomization.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study Treatment1/6 (16.7%)1/6 (16.7%)0/6 (0%)
Placebo Control4/5 (80%)4/5 (80%)1/5 (20%)
Most frequent serious events
Most frequent serious events
EventStudy TreatmentPlacebo Control
Worsening of Acute Hypoxic Respiratory FailureRespiratory, thoracic and mediastinal disorders1/63/5
Worsening of ARDSRespiratory, thoracic and mediastinal disorders0/61/5
Hypercapnic Respiratory FailureRespiratory, thoracic and mediastinal disorders0/61/5
Most frequent other events
Most frequent other events
EventStudy TreatmentPlacebo Control
HypotensionCardiac disorders0/61/5

Baseline characteristics

Age, Customized
Age, Customized(Participants)Study TreatmentPlacebo ControlTotal
<65 years325
>65 years336
Sex: Female, Male
Sex: Female, Male(Participants)Study TreatmentPlacebo ControlTotal
Female325
Male336
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Study TreatmentPlacebo ControlTotal
Count of participants——0
08

Study locations

1 site
  • Ohio State University
    Columbus, Ohio 43210, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Jun 2021, 9 months.

Results were first posted in Jul 2025, 4 years 1 month after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 9 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Jun 30, 2020
StartActual
Sep 15, 2020
Primary completionActual
Jun 29, 2021
CompletionActual
Jun 29, 2021
Results first posted
Jul 31, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04452669
Lead sponsor
Aerogen Pharma Limited
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Sep 15, 2020
Primary completion
Jun 29, 2021
Completion
Jun 29, 2021
Results posted
Jul 31, 2025
Last update
Jul 31, 2025

Study contacts

Veronica Franco, MD
principal investigator · Ohio State University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoprostenol

Start the discussion